Serum Tumor Markers In Evaluating The Effects Of Advanced Colorectal Cancer Treated With XELOX And FOLFIRI

Objective: To compare the efficacy and toxicity of the XELOX and FOLFIRI regimens as first-line treatment for patients with advanced colorectal cancer. By observing the changes of tumor markers associated colorectal cancer before and after the treatment of XELOX and FOLFIRI, to compare the coincidence rate of tumor markers evaluation and the clinical effect evaluation in different chemotherapy regimens,detection the value of tumor markers in the chemotherapy.To sum up the tumor markers with high efficacy evaluation of clinical value with XELOX and FOLFIRI regimens in the treatment of advanced colorectal cancer.Methods: Randomly assigned 51 patients who were diagnosed with advanced colorectal cancer, respectively was treated with XELOX or FOLFIRI regimen,comparison the response rate and toxicity of the two regimens.The CEA,CA19-9,CA242,CA125 were measured before and after treatment by multiple tumor marker protein chip detective system. Comparison the coinci- dence rate of tumor markers evaluation and the clinical effect evaluation of the two chemotherapy regimens.Results: The group study included 51 patients with advanced colorectal cancer,25 patients treated with a total of 110 cycles XELOX regimen,26 patients treated with a total of 106 cycles FOLFIRI regimen, the response rate of the XELOX regimen and the FOLFIRI regimen was 44.0%,42.3% respectively,there were no statistically significant between the two groups (P>0.05). CEA, CA19-9, CA242 after than before chemotherapy were sign- ificantly lower in the two groups, there were significant differences (P<0.05). CA125 after than before chemotherapy slightly decreased, but no significant difference (P>0.05). XELOX group in accordance with the CEA, CA19-9,CA242,CA125 for the overall coincidence rate of tumor markers evaluation and the clinical effect evaluation(RR+SD+PD). The coincidence rate of CEA up to 68.0%, CA125 have lowest compliance rate, only 36.0%. FOLFIRI group in accordance with the CEA, CA19-9, CA242, CA125 for the overall coincidence rate of tumor markers evaluation and the clinical effect evaluation (RR+SD+PD). The coincidence rate of CEA up to 65.4%, CA125 have lowest compliance rate, only 30.0%. The coincidence rate of the corresponding tumor markers in the two programs have no significant difference.The coincidence rate of CEA, CA19-9, CA242 were better, over 50%, prompted them to monitor the effects of chemotherapy have a certain advantage. Joint detection the tumor markers CEA, CA19-9, CA242 in XELOX group,the total coincidence rate can reach 83.5%. Joint detection the tumor markers CEA, CA19-9, CA242 in FOLFIRI group,the total coincidence rate can reach 81.2%.Conclusion: The regimens of XELOX and FOLFIRI have good effect for first-line treatment of advanced colorectal cancer, while side effects can be foreseen, reversible, and easy to handle, the two regimens have good security. Joint detection the tumor markers CEA, CA19-9, CA242 can help judge the efficacy of advanced colorectal cancer, have an important role in evaluating the effects of chemotherapy.